Treatment for Rare Autoimmune Disorder Receives FDA Approval
Dec 04, 2018
“This FDA approval marks the arrival of a first-in-class therapy for a rare and devastating condition with limited treatment options,” Gary Ingenito, MD, PhD, chief medical officer and head of regulatory affairs at Catalyst, said in a statement.2 “We extend our deepest gratitude to the patients who participated in the Firdapse clinical trials and their families and caregivers who supported them.”
Share It :- twiter
- Google Plus
